Patent Application
20130217889
Asymmetric phase transfer catalysis has been recognized as a convenient and powerful methodology in organic chemistry. This synthetic approach provides many advantages, including simple procedure, mild conditions, suitability for large scale reactions, and safety.
Various chiral phase transfer catalysts have been developed in the past thirty years, e.g., N-alkylated cinchomimium halide and N-spiro chiral ammonium salt. See O'Donnell et al., J. Am. Chem. Soc., 1989, 111, 2353; Ooi et al., J. Am. Chem. Soc., 1999, 121, 6519.
Yet, there is a need for less expensive and more efficient chiral phase transfer catalysts.
This invention is based on the discovery that certain pentanidium compounds can be used as chiral phase transfer catalysts. The term “pentanidium compounds” herein refers to alkylated or arylated salts of pentanidines that contain five nitrogen atoms in conjugation.
In one aspect, this invention features pentanidium compounds of formula (I):
In this formula, each of R1 and R8, independently, is C1-C10 alkyl, C3-C20 cycloalkyl, C3-C20 heterocycloalkyl, aryl, or heteroaryl; or R1 and R8 form C1-C10 alkyl, C3-C20 cycloalkyl, C3-C20 heterocycloalkyl, aryl, or heteroaryl; each of R2, R3, R6, and R7, independently, is H, C1-C10 alkyl, C3-C20 cycloalkyl, C3-C20 heterocycloalkyl, aryl, or heteroaryl; or R2 and R3, together with the two carbon atoms to which they are attached, form C4-C20 cycloalkyl, C4-C20 heterocycloalkyl, aryl, or heteroaryl; or R6 and R7, together with the two carbon atoms to which they are attached, form C4-C20 cycloalkyl, C4-C20 heterocycloalkyl, aryl, or heteroaryl; each of R4 and R5, independently, is C1-C10 alkyl, C3-C20 cycloalkyl, C3-C20 heterocycloalkyl, aryl, or heteroaryl; X− is a halide ion, a hydroxide ion, a tetrafluoroboric acid ion, a nitric acid anion, a hexaflorophosphoric acid ion, a tetrakis(3,5-bis(trifluoromethyl)phenyl)borate, a sulfuric acid anion, a phosphoric acid anion, a citric acid anion, a methanesulfonic acid anion, a trifluoroacetic acid anion, a malic acid anion, a tartaric acid anion, a fumaric acid anion, a glutamic acid anion, a glucuronic acid anion, a lactic acid anion, a glutaric acid anion, a maleic acid anion, an acetic acid anion, or a p-toluenesulfonic acid ion; and at least one of the four carbon atoms to which R2, R3, R6, and R7 are attached has an R or S configuration.
One subset of the above-described compounds are those in which R1 is identical to R8, R2 is identical to R7, R3 is identical to R6, and R4 is identical to R5. In these compounds, all the carbon atoms to which R2, R3, R6, and R7 are attached have an R or S configuration (e.g., all of them having an R configuration, or all of them having a S configuration); each of R2, R3, R6, and R7, independently, is aryl or heteroaryl, or R2 and R3, together with the two carbon atoms to which they are attached, form C4-C20 cycloalkyl, and R6 and R7, together with the two carbon atoms to which they are attached, form C4-C20 cycloalkyl; and each of R1, R4, R5, and R8, independently, is C1-C10 alkyl.
Another subset of the compounds described above are those in which R1 is identical to R8, each of R2 and R7 is H, and R4 is identical to R5; all the carbon atoms to which R3 and R6 are attached have an R or S configuration; each of R3 and R6, independently, is aryl or heteroaryl; and each of R1, R4, R5, and R8, independently, is C1-C10 alkyl.
Still another subset of the compounds described above are those in which R1 is identical to R8, each of R3 and R6 is H, and R4 is identical to R5; all the carbon atoms to which R2 and R7 are attached have an R or S configuration; each of R2 and R7, independently, is aryl or heteroaryl; and each of R1, R4, R5, and R8, independently, is C1-C10 alkyl.
The term “alkyl” refers to a saturated hydrocarbon moiety, either linear or branched. The term “cycloalkyl” refers to a saturated, cyclic hydrocarbon moiety, such as cyclohexyl. The tenn “heterocycloalkyl” refers to a saturated, cyclic moiety having at least one ring heteroatom (e.g., N, O, or S), such as 4-tetrahydropyranyl. The term “aryl” refers to a hydrocarbon moiety having one or more aromatic rings. Examples of aryl moieties include phenyl (Ph), phenylene, naphthyl, naphthylene, pyrenyl, anthryl, and phenanthryl. The term “heteroaryl” refers to a moiety having one or more aromatic rings that contain at least one heteroatom (e.g., N, O, or S). Examples of heteroaryl moieties include furyl, furylene, fluorenyl, pyrrolyl, thienyl, oxazolyl, imidazolyl, thiazolyl, pyridyl, pyrimidinyl, quinazolinyl, quinolyl, isoquinolyl and indolyl.
Alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl mentioned herein include both substituted and unsubstituted moieties, unless specified otherwise. Possible substituents on cycloalkyl, heterocycloalkyl, aryl, and heteroaryl include, but are not limited to, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C20 cycloalkyl, C3-C20 cycloalkenyl, C1-C20 heterocycloalkyl, C1-C20 heterocycloalkenyl, C1-C10 alkoxy, aryl, aryloxy, heteroaryl, heteroaryloxy, amino, C1-C10 alkylamino, C1-C20 diallcylamino, arylamino, diarylamino, C1-C10 alkylsulfonamino, arylsulfonamino, C1-C10 alkylimino, arylimino, C1-C10 alkylsulfonimino, arylsulfonimino, hydroxyl, halo, thio, C1-C10 alkylthio, arylthio, C1-C10 alkylsulfonyl, arylsulfonyl, acylamino, aminoacyl, aminothioacyl, amido, amidino, guanidine, ureido, thioureido, cyano, nitro, nitroso, azido, acyl, thioacyl, acyloxy, carboxyl, and carboxylic ester. On the other hand, possible substituents on alkyl include all of the above-recited substituents except C1-C10 alkyl. Cycloalkyl, heterocycloalkyl, aryl, and heteroaryl can also be fused with each other.
In another aspect, this invention features a method of preparing pentanidium compounds of formula (I) shown above.
The method includes reacting a compound of formula (II) with a compound of formula (III). The two formulae are shown below:
In formulae (II) and (III), R1 to R8, and X− are defined above. Also, at least one of the four carbon atoms to which R2, R3, R6, and R7 are attached has an R or S configuration.
In still another aspect, this invention features a method of preparing a chiral compound of formula (IV):
This method includes reacting an enone of formula (V):
with a Schiff base of formula (VI):
in the presence of a catalyst, which is a compound of formula (I) shown above.
In formulae (IV), (V), and (VI), R11 is H, C1-C10 alkyl, C3-C20 cycloalkyl, C3-C20 heterocycloalkyl, aryl, or heteroaryl; each of R12 and R13, independently, is H, C1-C10 alkyl, C3-C20 cycloalkyl, C3-C20 heterocycloalkyl, aryl, or heteroaryl; or R12 and R13, together with the carbon atom to which they are attached, is C3-C20 cycloalkyl, or C3-C20 heterocycloalkyl; each of R14 and R15, independently, is H, C1-C10 alkyl, C3-C20 cycloalkyl, C3-C20 heterocycloalkyl, aryl, or heteroaryl; or R14 and R15, together with the carbon atom to which they are attached, is C3-C20 cycloalkyl, or C3-C20 heterocycloalkyl; R16 is C1-C10 alkyl, C3-C20 cycloalkyl, C3-C20 heterocycloalkyl, aryl, or heteroaryl.
The details of one or more embodiments of the invention are set forth in the description below. Other features, objects, and advantages of the invention will be apparent from the description and also from the claims.
The pentanidium compounds of this invention can be prepared by methods well known in the art, e.g., Ma et al., J. Am. Chem. Soc., 2011, 133, 2828. The route shown in Scheme 1 below exemplifies synthesis of these compounds.
Specifically, a diamine compound i can react with triphosgene in the presence of a base to form compound ii, which can be converted into compound iii through alkylation. Compound iii can be treated with oxalyl chloride under a heating condition to yield an imidazoline salt. This salt can react with ammonia to obtain imidazolidin-2-imine iv, which in turn is treated with an imidzaoline salt to form the compounds of the invention, e.g., Compound 1a-1f shown below:
A pentanidium compound thus synthesized can be purified by any suitable method, such as column chromatography, high-pressure liquid chromatography, or recrystallization.
Other pentanidium compounds of this invention can be prepared using other suitable starting materials through the above-described synthetic routes and others known in the art. The methods set forth above may also additionally include steps to add or remove suitable protecting groups in order to ultimately allow synthesis of the pentanidium compounds. In addition, various synthetic steps may be performed in an alternate sequence or order to give the desired compounds. Synthetic chemistry transformations and protecting group methodologies (protection and deprotection) useful in synthesizing applicable pentanidium compounds are known in the art and include, for example, those described in R. Larock, Comprehensive Organic Transformations, VCH Publishers (1989); T. W. Greene and P. G. M. Wuts, Protective Groups in Organic Synthesis, 2rd Ed., John Wiley and Sons (1991); L. Fieser and M. Fieser, Fieser and Fieser's Reagents for Organic Synthesis, John Wiley and Sons (1994); and L. Paquette, ed., Encyclopedia of Reagents for Organic Synthesis, John Wiley and Sons (1995) and subsequent editions thereof.
The pentanidium compounds described herein may contain a non-aromatic double bond and one or more asymmetric centers. Thus, they can occur as single enantiomers, individual diastereomers, diastereomeric mixtures, and cis- or trans-isomeric forms. All such isomeric forms are contemplated.
Also within the scope of this invention is a method of preparing the pentanidium compounds described above.
These pentanidium compounds can be used as chiral phase transfer catalysts in asymmetric reactions, such as asymmetric alkylation, Michael addition, aldol reaction.
The specific examples below are to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever. Without further elaboration, it is believed that one skilled in the art can, based on the description herein, utilize the present invention to its fullest extent. All publications cited herein are hereby incorporated by reference in their entirety.
1H and 13C NMR spectra were recorded on a Bruker ACF300 (300 MHz), Bruker DPX300 (300 MHz), 500 MHz Bruker DRX NMR spectrometer, or AMX500 (500 MHz) spectrometer. Chemical shifts were reported in parts per million (ppm). The residual solvent peak was used as an internal reference. Low resolution mass spectra were obtained on a Finnigan/MAT LCQ spectrometer in ESI mode. High resolution mass spectra were obtained on a Finnigan/MAT 95XL-T spectrometer. Enantiomeric excess values were determined by chiral HPLC analysis on Dionex Ultimate 3000 HPLC units, including a Ultimate 3000 Pump, Ultimate 3000 variable Detectors. Optical rotations were recorded on a Jasco DIP-1000 polarimeter with a sodium lamp of wavelength 589 nm and reported as follows; T °Cλ [α] (c=g/100 mL, solvent). Melting points were determined on a BÜCHI B-540 melting point apparatus. Flash chromatography separations were performed on Merck 60 (0.040-0.063 mm) mesh silica gel. Toluene was distilled from sodium/benzophenone and stored under N2 atmosphere. MeCN was dried by Molecular Sieve. Dichloromethane was distilled from CaH2 and stored under N2 atmosphere. Other reagents and solvents were commercial grade and were used as supplied without further purification, unless otherwise stated. Experiments involving moisture and/or air sensitive components were performed under a positive pressure of nitrogen in oven-dried glassware equipped with a rubber septum inlet. Reactions requiring temperatures −20 ° C. were stirred in either Thermo Neslab CB-60 with Cryotrol temperature controller or Eyela PSL-1400 with digital temperature controller cryobaths. Isopropanol was used as the bath medium. All experiments were monitored by analytical thin layer chromatography (TLC). Instrumentations Proton nuclear magnetic resonance (1H NMR), carbon NMR (13C NMR), phosphorous NMR (31P NMR), and fluorine NMR (19F NMR) spectra were recorded in CDCl3 otherwise stated. 1H (500.1331 MHz), 13C (125.7710 MHz) with complete proton decoupling, 31P (121 MHz) with complete proton decoupling, and 1H NOESY NMRs were performed on a 500 MHz Bruker DRX NMR spectrometer. 19F NMR (282.3761 MHz) was performed on a 300 MHz Bruker ACF spectrometer. All compounds synthesized were stored in a −34° C. freezer.
Provided below are the scheme and detailed procedures for synthesizing intermediates (Compounds B-D) and Compound 1a from Compound A.
To a solution of Compound A, a chiral diamine (2.12 g, 10 mmol) and Et3N (4.1 ml, 30 mmol) in CH2Cl2 (25 mL), was added triphosgene (977 mg, 3.3 mmol, dissolved in 5 mL CH2Cl2) in a dropwise manner, keeping the temperature lower than 5° C. all the time. After allowing the temperature to rise to room temperature, an additional 4-5 hours of stirring was required to allow the reaction to complete (monitored by TLC). After diamine A was completely consumed, reaction was quenched by water (20 mL) and extracted using CH2Cl2 3 times (30 mL×3). The combined organic layer was washed by brine and dried by Na2SO4. Solvent was removed under reduced pressure. Compound B was pale yellow solid, which can be used in the next step without any further purification. 1H NMR (300 MHz, CDCl3): δ 7.38-7.34 (m, 6H), 7.27-7.30 (m, 4H), 5.83 (s, 2H), 4.57 (s, 2H). 13C NMR (126 MHz, CDCl3) δ 163.1, 140.2, 128.7, 128.2, 126.4, 65.9; LRMS (ESI) m/z 239.1 (M+H+), HRMS (ESI) m/z 239.1185 ([M+H+]), calc. for [C15H14N2O+H+]239.1179.
To a suspension of NaH (720 mg, 30 mmol, 3.0 equiv) in THF (15 mL) was added a solution of Compound B (from step 1) in THF (20 mL). After 0.5 h, 2.3 mL of MeI (37 mmol, 3.7 equiv) was added in one portion. Upon completion of the reaction (monitored by TLC), the mixture was filtered through a short pad of Celite. Solvent was removed under reduced pressure and Compound C was obtained by flash chromatography (silica gel, hexane-ethyl acetate 3:1), as a white solid, 2.10 g (2 steps, 80% overall yield). 1HNMR (300 MHz, CDCl3): δ 7.34-7.32 (m, 6H), 7.14-7.11 (m, 4H), 4.07 (s, 2H), 2.69 (s, 6H); 13C NMR (126 MHz, CDCl3) δ 161.7, 137.9, 128.7, 128.3, 127.2, 70.2, 29.9; LRMS (ESI) m/z 267.1 (M+H+), HRMS (ESI) m/z 267.1497 ([M+H+]), calc. for [C17H18N2O +H+]267.1492.
A 100 mL RBF was charged with a solution of Compound C (1.60 g, 6 mmol, 1 equiv) in toluene (40 mL) with a condenser under N2 atmosphere. (COCl)2 (5.2 mL, 60 mmol, 10 equiv) was added via syringe in one portion. The mixture was refluxed overnight until C was completely reacted. Toluene was removed under reduced pressure and solid imidazoline salt (1.93 g) was obtained for the next step without any purification. Note that imidazoline salt is air and moisture sensitive, which should be stored under nitrogen atmosphere or vacuum.
Separate half of imidazoline salt for the step 5. The other part (960 mg) was dissolved in dry MeCN/MeOH (volume ratio 1:1, 20 mL), NH3 was bubbled into the solution at 0° C. for 0.5 h. Then, the seal tube was sealed and placed in 60° C. oil bath. After stirring overnight to complete reaction, pressure was released and water was added (40 mL). The mixture was extracted by CH2Cl2 3 times (20 mL×3). The combined organic layer was dried by Na2SO4. After removing solvent under reduced pressure, Compound D was obtained as a brown solid, 801 mg, >99% yield. 1H NMR (300 MHz, CDCl3): δ 7.17-7.14 (m, 6H), 6.99-6.97 (m, 4H), 4.48 (b, 1H), 3.87 (s, 2H), 2.52 (s, 6H); 13C NMR (125.77 MHz, CDCl3): δ 163.3, 137.9, 128.6, 128.2, 127.4, 72.1, 31.4; LRMS (ESI) m/z 266.1 (M+H+), HRMS (ESI) m/z 266.1664 ([M+H+]), calc. for [C17H19N3+H+]266.1652.
To a solution of Compound D (800 mg, 3.06 mmol) and Et3N (0.45 mL, 3.24 mmol) in MeCN (15 mL) was added a solution of imidazoline salt (from step 4, 970 mg, 1.0 equiv) in dry MeCN (10 mL) in a dropwise manner. The reaction mixture was stirred until the reaction was completed. Reaction was quenched by water (20 mL), and extracted using CH2Cl2 3 times (20 mL×3). The combined organic layer was dried by Na2SO4. Solvent was removed under reduced pressure. The brown solid obtained was re-crystallized by CH2Cl2/ethyl acetate solvent system. Compound la was isolated as a white solid, 820 mg, 48% yield. mp 276-278° C.; 1H NMR (500 MHz, CDCl3): δ 7.35-7.34 (m, 12H), 7.24-7.21 (m, 8H), 4.67 (s, 4H), 2.93 (s, 12H); 13C NMR (126 MHz, CDCl3) δ 159.5, 135.4, 129.3, 129.3, 127.6, 72.6, 32.5; LRMS (ESI) m/z 514.5 ([M−Cl−])+, HRMS (ESI) m/z 514.2970 ([M−Cl−])+, calc. for [C34H36N5+]514.2965. [α]D29=+171.2 (c 1.18, CHCl3).
Compound 1b was prepared in a manner similar to that described in Example 1, with two additional steps described below. See Ryoda, A et al., JOC, 2008, 73, 133.
White solid. 1H NMR (500 MHz, CDCl3) δ 7.42-7.40 (m, 12H), 7.17-7.15 (m, 8H), 4.53 (s, 4H), 4.31-4.24 (m, 4H), 3.05-3.03 (m, 4H), 1.16 (t, J=7.5, 12H); 13C NMR (126 MHz, CDCl3) δ 157.1, 136.5, 129.4, 129.4, 127.0, 69.8, 39.0, 11.3; LRMS (ESI) m/z 570.5 ([M—Cl−])+, HRMS (ESI) m/z 570.3586 ([M−Cl−])+, calc. for [C38H44N5+] 570.3591.
Compound 1c was prepared in a manner similar to that described in Example 1 except that a different starting material, i.e., (1S,2S)-1,2-bis(4-methoxyphenyl)ethane-1,2-diamine, was used.
White solid; 56% yield. 1H NMR (300 MHz, CDCl3) δ 7.19 (d, J=8.7 Hz, 8H), 6.89 (d, J=8.7 Hz, 8H), 4.60 (s, 4H), 3.79 (s, 12H), 2.90 (s, 12H); 13C NMR (75 MHz, CDCl3) δ 160.2, 159.2, 129.0, 127.3, 114.6, 72.2, 55.2, 32.3; LRMS (ESI) m/z 634.5 ([M−Cl−])+, HRMS (ESI) m/z 634.3403 ([M−Cl−])+, calc. for [C38H44N5O4+] 634.3388.
Compound 1d was synthesized by reacting Compound la (prepared in Example 1) with sodium tetrafluoroborate in the following manner:
White solid; 98% yield. 1H NMR (300 MHz, CDCl3) δ 7.40-7.37 (m, 12H), 7.26-7.22 (m, 8H), 4.62 (s, 4H), 2.91 (s, 12H); 13C NMR (75 MHz, CDCl3) δ 159.5, 135.5, 129.30, 129.2, 127.6, 104.9, 72.7, 32.2; 19F NMR (282 MHz, CDCl3) δ-76.59.
Compound le was synthesized by reacting Compound la (prepared in Example 1) with sodium hexafluorophosphate in the following manner:
White solid; 99% yield. 1H NMR (300 MHz, CDCl3) δ 7.43-7.40 (m, 12H), 7.27-7.24 (m, 8H), 4.63 (s, 4H), 2.92 (s, 12H); 13C NMR (75 MHz, CDCl3) δ 159.4, 135.4, 129.4, 129.3, 127.6, 72.7, 32.2; 19F NMR (282 MHz, CDCl3) δ 3.32 (d, 710Hz). 31P NMR (121 MHz, CDCl3) δ-143.6 (tt, J1=709 Hz, 1418 Hz).
Compound 1f was prepared in a manner similar to that described in Example 1 except that a different starting material, i.e., (1S,2S)-cyclohexane-1,2-diamine, was used. Also, the compound thus-synthesized was purified by flash chromatography (silica gel, CH2Cl2/MeOH, 50:1).
Colorless oil. 1H NMR (300 MHz, CDCl3) δ 3.01-2.99 (m, 4H), 2.79 (s, 12H), 2.19-2.10 (m, 8H), 1.93 (d, J =6.2 Hz, 4H), 1.45-1.42 (m, 4H); 13C NMR (75 MHz, CDCl3) δ 162.7, 66.2, 31.4, 27.8, 23.8; LRMS (ESI) m/z 318.5 ([M−Cl−])+, HRMS (ESI) m/z 318.2659 ([M−Cl−])+, calc. for [C18H32N5+] 318.2652.
Table 1 below lists Michael addition of a Schiff Base (i.e., Compound 2) with various vinyl ketones and acrylates (i.e., Compounds 3a-3f) to yield Compounds 4a-4f in the presence of Compound la as the catalyst. Compounds 3a-3f were prepared following the procedures described in Ma et al., J. Am. Chem. Soc., 2011, 133, 2828.
aReactions were performed by using Compound 2 (0.06 mmol) and Compounds 3a-3f (0.12 mmol) in 0.6 ml mesitylene for indicated time.
bYield of isolated product.
cDetermined by HPLC analysis using a Chiralcel OD-H column.
d0.1 mol % of catalyst was used.
e0.03 mol % of catalyst was used.
tert-Butyl glycinate benzophenone Schiff base, Compound 2 (17.7 mg, 0.06 mmol, 1.0 equiv), (S, S)-1a (0.66 mg, 0.0012 mmol, 0.02 equiv) and Cs2CO3 (97 mg, 0.2 mmol, 5.0 equiv) were placed in mesitylene (0.6 mL) and stirred at −20 ° C. for 10 min, then ethyl vinyl keton 3a (12.8 μL, 0.12 mmol, 2.0 equiv) was added by syringe in one portion. The reaction mixture was stirred at −20° C. and monitored by TLC. After indicated time, upon complete consumption of 2, the reaction mixture was directly loaded onto a short silica gel column, followed by gradient elution with hexane/ethyl acetate (15/1-12/1 ratio). After removing the solvent, product 4a (20.9 mg, 92% yield) was obtained as colorless oil. 1H NMR (300 MHz, CDCl3) δ 7.67-7.58 (m, 2H), 7.47-7.27 (m, 6H), 7.16 (dd, J =6.4, 3.1 Hz, 2H), 3.95 (t, J =6.1 Hz, 1H), 2.59-2.32 (m, 4H), 2.15 (dd, J=13.6, 7.6 Hz, 2H), 1.43 (s, 9H), 1.01 (t, J=7.3 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 210.8, 170.9, 170.3, 139.4, 136.4, 130.2, 128.5, 127.9, 127.6, 81.0, 64.7, 38.4, 35.8, 27.8, 7.67; LRMS (ESI) m/z 402.1 (M+Na+), HRMS (ESI) m/z 402.2037 ([M+Na+]), calc. for [C24H29NO3+Na+] 402.2040; [α]D29=+72.8 (c 1.55, CHCl3); HPLC analysis: Chiralcel OD-H (Hex/IPA=92/8, 0.8 mL/min, 230 nm, 23° C.), 5.9 (major), 8.0 min, 93% ee.
Colorless oil; 86% yield. 1H NMR (300 MHz, CDCl3) δ 7.67-7.58 (m, 2H), 7.47-7.27 (m, 6H), 7.17-7.15 (m, 2H), 3.95 (t, J =6.1 Hz, 1H), 2.59-2.45 (m, 2H), 2.35-2.15 (m, 2H), 2.12 (s, 3H), 1.43 (s, 9H);13C NMR (75 MHz, CDCl3) δ 208.2, 170.9, 170.4, 139.4, 136.4, 130.2, 128.7, 128.5, 128.4, 128.4, 127.9, 127.6, 81.1, 64.6, 39.7, 29.8, 28.0, 27.7; LRMS (ESI) m/z 388.1 (M+Na+), HRMS (ESI) m/z 388.1900 ([M+Na+]), calc. for [C23H27NO3+Na+] 388.1883; [α]D29=+64.2 (c 1.30, CHCl3); HPLC analysis: Chiralcel OD-H (Hex/IPA=92/8, 0.8 mL/min, 210 nm, 23° C.), 6.5 (major), 7.2 min, 91% ee.
Colorless oil; 97% yield. 1H NMR (500 MHz, CDCl3) δ 7.66-7.60 (m, 2H), 7.47-7.41 (m, 3H), 7.38-7.37 (m, 1H), 7.32 (t, J=7.5 Hz, 2H), 7.19-7.13 (m, 2H), 3.95 (t, J=12.1 Hz,1H), 2.55-2.42 (m, 2H), 2.41-2.33 (m, 2H), 2.14 (dd, J=13.8, 7.5 Hz, 2H), 1.54-1.47 (m, 2H), 1.43 (s, 9H), 1.27 (dd, J=15.0, 7.4 Hz, 2H), 0.88 (t, J=7.3 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 210.6, 171.0, 170.3, 139.4, 136.4, 130.2, 128.7, 128.5, 128.4, 127.9, 127.6, 81.0, 64.7, 42.4, 38.8, 28.0, 27.7, 25.8, 22.2, 13.8; LRMS (ESD m/z 430.1 (M+Na+), HRMS (ESI) m/z 430.2364 ([M+Na+]), calc. for [C26H33NO3+Na+] 430.2353; [α]D29=+43.4 (c 1.62, CHCl3); HPLC analysis: Chiralcel OD-H+Chiralcel OD-H (Hex/IPA=95/5, 0.5 mL/min, 230 nm, 23° C.), 19.4 (major), 23.6 min, 93% ee.
Colorless oil; 50% yield. 1H NMR (300 MHz, CDCl3) δ 7.95-7.93 (m, 2H), 7.65 (d, J=7.1 Hz, 2H), 7.56-7.53 (m, 1H), 7.45-7.39 (m, 6H), 7.32 (t, J=7.3 Hz, 2H), 7.15-7.13 (m, 2H), 4.08 (t, J=6.0 Hz, 1H), 3.16-3.01 (m, 2H), 2.33 (dd, J=13.3, 6.9 Hz, 2H), 1.45 (s, 9H);13C NMR (75 MHz, CDCl3) δ 199.6, 176.1, 171.0, 170.1, 136.8, 132.9, 132.4, 130.3, 130.0, 128.8, 128.5, 128.4, 128.2, 128.1, 128.0, 127.7, 64.7, 34.7, 28.0; LRMS (ESI) m/z 450.1 (M+Na+), HRMS (ESI) m/z 450.2056 ([M+Na+]), calc. for [C28H29NO3 +Na+ +450.2040; [α]D29=19.1 (c 0.5, CHCl3); HPLC analysis: Chiralcel OD-H (Hex/IPA=92/8, 0.8 mL/min, 254 nm, 23° C.), 6.5 (major), 8.8 min, 88% ee.
Colorless oil; 71% yield. 1H NMR (500 MHz, CDCl3) δ 7.67-7.6 (m, 2H), 7.47-7.41 (m, 3H), 7.40-7.35 (m, 1H), 7.35-7.29 (m, 2H), 7.20-7.14 (m, 2H), 4.05 (q, J=7.1 Hz, 2H), 3.97 (dd, J=6.9, 5.7 Hz, 1H), 2.35 (dd, J=8.6, 6.8 Hz, 2H), 2.33-2.21 (m, 2H), 1.44 (s, 9H), 1.19 (t, J=7.1 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 210.8, 170.9, 170.3, 139.4, 136.4, 130.2, 128-.5, 127.9, 127.6, 81.0, 64.7, 38.4, 35.8, 27.8, 7.67; LRMS (ESI) m/z 418.1 (M+Na+), HRMS (ESI) m/z 418.1997 ([M+Na+]), calc. for [C24H29NO4+Na+] 418.1989; [α]D29=+ 75.2 (c 1.38, CHCl3); HPLC analysis: Chiralcel OD-H (Hex/IPA=95/5, 0.5 mL/min, 254 nm, 23° C.), 9.5 (major), 11.6 min, 97% ee.
Colorless oil; 80% yield. 1H NMR (500 MHz, CDCl3) δ 7.67-7.63 (m, 2H), 7.44-7.39 (m, 3H), 7.39-7.36 (m, 1H), 7.36-7.27 (m, 7H), 7.18-7.13 (m, 2H), 5.04 (s, 2H), 3.98 (dd, J=7.4, 5.2 Hz, 1H), 2.43 (dd, J=11.3, 5.2 Hz, 2H), 2.31-2.20 (m, 2H), 1.44 (s, 9H). 13C NMR (75 MHz, CDCl3) δ 172.9, 170.7, 139.4, 136.4, 135.9, 130.2, 128.7, 128.5, 128.4, 128.3, 128.1, 127.9, 127.6, 81.1, 66.1, 64.8, 30.7, 28.5, 28.0; LRMS (ESI) m/z 480.1 (M +Na+), HRMS (ESI) m/z 480.2165 ([M +Na+]), calc. for [C29H31NO4+Na+] 480.2145; [α]D29=+57.5 (c 1.72, CHCl3); HPLC analysis: Chiralpak AD-H+Chiralcel OD-H (Hex/IPA=92/8, 0.8 mL/min, 210 nm, 23° C.), 12.9 (major), 13.8 min, 96% ee.
Table 2 below lists Michael addition of a Schiff Base (i.e., Compound 2) with various chalcones (i.e., Compounds 5a-5p) to yield Compounds 6a-6p in the presence of Compound la as the catalyst. Compounds 5a-5p were prepared following the procedures described in Ma et al., J. Am. Chem. Soc., 2011, 133, 2828.
aReactions were performed by using Compound 2 (0.06 mmol) and Compounds 5a-5p (0.072 mmol) in 0.6 ml mesitylene for indicated time.
bYield of isolated product.
cDetermined by HPLC analysis using Chiralcel OD-H column. Only one diastereomer was observed, absolute configuration was verified by single crystal X-ray diffraction of 7.
d2 (0.1 mmol), 5f (0.12 mmol) and 2.5 equiv Cs2CO3 was used with catalyst loading of 0.05 mol %.
tert-Butyl glycinate benzophenone Schiff base 2 (17.7 mg, 0.06 mmol, 1.0 equiv), (S, S)-1a (0.66 mg, 0.0012 mmol, 0.02 equiv) and Cs2CO3 (97 mg, 0.2 mmol, 5.0 equiv) were placed in mesitylene (0.6 mL) and stirred at −20° C. for 10 min, followed by chalcone 5a (15.0 mg, 0.072 mmol, 1.2 equiv). The reaction mixture was stirred at −20° C. and monitored by TLC. After indicated time, upon complete consumption of 2, the reaction mixture was directly loaded onto a short silica gel column, followed by gradient elution with hexane/ethyl acetate (15/1-12/1 ratio). After removing the solvent, product 6a (29.6 mg, 98% yield) was obtained as colorless oil. 1H NMR (300 MHz, CDCl3) δ 8.00-7.96 (m, 2H), 7.74-7.64 (m, 2H), 7.58-7.27 (m, 9H), 7.22-7.08 (m, 5H), 6.73 (d, J=6.4 Hz, 2H), 4.27-4.16 (m, 2H), 3.83-3.70 (m, 1H), 3.69-3.57 (m, 1H), 1.33 (s, 9H); 13C NMR (75 MHz, CDCl3) δ 198.6, 171.0, 170.0, 141.3, 139.3, 137.2, 136.2, 132.7, 130.3, 128.8, 128.5, 128.4, 128.3, 128.1, 128.0, 127.9, 127.5, 126.5, 81.2, 70.9, 44.8, 40.0, 27.8; LRMS (ESI) m/z 526.1 (M+Na+), HRMS (ESI) m/z 526.2373 ([M+Na+]), calc. for [C34H33NO3+Na+] 526.2353; [α]D29=+58.8 (c 2.48, CHCl3); HPLC analysis: Chiralcel OD-H (Hex/IPA=95/5, 0.5 mL/min, 230 nm, 23° C.), 10.9 (major), 21.5 min, 92% ee.
Colorless oil; 91% yield. 1H NMR (500 MHz, CDCl3) δ 8.10 (d, J=8.2 Hz, 1H), 8.05-7.98 (m, 2H), 7.80 (d, J=7.6 Hz, 1H), 7.70-7.60 (m, 3H), 7.56-7.52 (m, 1H), 7.48-7.36 (m, 5H), 7.33 (t, J=7.4 Hz, 2H), 7.30-7.23 (m, 2H), 7.11 (t, J=7.4 Hz, 1H), 6.96 (t, J=7.4 Hz, 2H), 6.27 (s, 2H), 5.20-5.10 (m, 1H), 4.30 (d, J=3.7 Hz, 1H), 4.11 (dd, J=17.3, 9.8 Hz, 1H), 3.81 (dd, J=17.3, 4.2 Hz, 1H), 1.35 (s, 9H); 13C NMR (75 MHz, CDCl3) δ 198.5, 171.1, 170.3, 139.3, 137.2, 135.8, 133.9, 132.7, 131.7, 130.2, 128.7, 128.5, 128.4, 128.1, 127.9, 127.7, 127.1, 126.9, 125.9, 125.2, 124.8, 123.0, 81.3, 69.2, 39.2, 27.8; LRMS (ESI) m/z 576.1 (M+Na+), HRMS (ESI) m/z 576.2494 ([M+Na+]), calc. for [C38H35NO3 +Na+] 576.2509; [α]D29=+87.8 (c2.79, CHCl3); HPLC analysis: Chiralcel OD-H (Hex/IPA=95/5, 0.5 mL/min, 254 nm, 23° C.), 12.1 (major), 14.0 min, 92% ee.
Colorless oil; 93% yield. 1H NMR (500 MHz, CDCl3) δ 7.98 (dd, J=5.1, 3.3 Hz, 2H), 7.74-7.54 (m, 5H), 7.60 (s, 1H), 7.55-7.52 (m, 1H), 7.45-7.30 (m, 9H), 7.22-7.19 (m, 2H), 6.64 (d, J=7.0 Hz, 2H), 4.40-4.37 (m, 1H), 4.29 (d, J=5.0 Hz, 1H), 3.89 (dd, J=17.0, 10.2 Hz, 1H), 3.72 (dd, J =17.0, 3.8 Hz, 1H), 1.31 (s, 9H); 13C NMR (126 MHz, CDCl3) δ 198.7, 171.2, 170.0, 141.1, 140.6, 139.4, 137.2, 136.3, 132.8, 130.4, 129.0, 128.9, 128.7, 128.5, 128.4, 128.2, 128.2, 128.1, 127.5, 127.0, 127.0, 126.8, 81.4, 70.9, 44.5, 39.9, 27.9; LRMS (ESI) m/z 576.1 (M+Na+), HRMS (ESI) m/z 576.2496 ([M+Na+]), calc. for [C38H35NO3+Na+] 576.2509; [α]D29=+44.8 (c 2.74, CHCl3); HPLC analysis: Chiralcel OD-H (Hex/IPA=95/5, 0.5 mL/min, 210 nm, 23° C.), 12.4 (major), 22.7 min, 90% ee.
Colorless oil; 88% yield. 1H NMR (500 MHz, CDCl3) δ 8.04 -7.94 (m, 2H), 7.72-7.65 (m, 2H), 7.56-7.51 (m, 3H), 7.48-7.34 (m, 10H), 7.30 (t, J=7.4 Hz, 3H), 7.21 (d, J=8.2 Hz, 2H), 6.73 (d, J=7.1 Hz, 2H), 4.26-4.20 (m, 2H), 3.81 (dd, J=17.0, 10.0 Hz, 1H), 3.66 (dd, J=17.0, 3.6 Hz, 1H), 1.34 (s, 9H); 13C NMR (126 MHz, CDCl3) δ 198.7, 171.2, 170.0, 141.1, 140.6, 139.4, 137.2, 136.3, 132.8, 130.4, 129.0, 128.9, 128.7, 128.5, 128.4, 128.2, 128.1, 127.5, 127.0, 127.0, 126.8, 81.4, 70.9, 44.5, 39.9, 27.9; LRMS (ESI) m/z 602.1 (M+Na+), HRMS (ESI) m/z 602.2664 ([M +Na+]), calc. for [C40H37NO3+Na+] 602.2677; [α]D29=+41.0 (c 0.98, CHCl3); HPLC analysis: Chiralcel OD-H (Hex/IPA=92/8, 0.8 mL/min, 254 nm, 23° C.), 9.4 (major), 13.1 min, 91% ee.
Colorless oil; 89% yield. 1H NMR (500 MHz, CDCl3) δ 7.95 (d, J=7.3 Hz, 2H), 7.70-7.66 (m, 2H), 7.54 (t, J=7.4 Hz, 1H), 7.46-7.32 (m, 8H), 7.11 (dd, J=8.6, 5.5 Hz, 2H), 6.86 (t, J=8.7 Hz, 2H), 6.77 (d, J=6.9 Hz, 2H),.4.22-4.09 (m, 2H), 3.69 (dd, J=16.9, 10.0 Hz, 1H), 3.60 (dd, J=16.9, 3.7 Hz, 1H), 1.33 (s, 9H); 13C NMR (126 MHz, CDCl3) δ 198.6, 171.3, 169.9, 162.6, 160.6, 139.3, 137.1, 136.2, 132.9, 130.5, 130.1, 130.0, 128.8, 128.5, 128.5, 128.3, 128.2, 128.1, 127.5, 115.0, 114.8, 81.4, 70.9, 44.1, 40.2, 27.9; LRMS (ESI) m/z 544.1 (M+Na+), HRMS (ESI) m/z 544.2258 ([M +Na+]), calc. for [C34H32FNO3+Na+] 544.2258; [α]D29=+ 54.5 (c 1.26, CHCl3); HPLC analysis: Chiralcel OD-H (Hex/IPA=95/5, 0.5 mL/min, 254 nm, 23° C.), 10.2 (major), 19.9 min, 90% ee.
Colorless oil; 98% yield. 1H NMR (500 MHz, CDCl3) δ 7.99-7.93 (m, 2H), 7.69-7.66 (m, 2H), 7.59-7.51 (m, 1H), 7.46-7.40 (m, 3H), 7.39-7.31 (m, 5H), 7.16-7.12 (m, 2H), 7.11-7.06 (m, 2H), 6.76 (d, J=6.9 Hz, 2H), 4.18-4.14 (m, 2H), 3.73 (dd, J=17.1, 9.7 Hz, 1H), 3.61 (dd, J=17.1, 3.4 Hz, 1H), 1.34 (s, 9H); 13C NMR (126 MHz, CDCl3) δ 198.4, 171.4, 169.8, 140.1, 139.3, 137.1, 136.2, 133.0, 132.3, 130.5, 129.9, 128.8, 128.5, 128.5, 128.3, 128.2, 128.2, 128.1, 127.5, 81.5, 70.7, 44.1, 39.9, 27.9; LRMS (ESI) m/z 560.0 (M+Na+), HRMS (ESI) m/z 560.1966 ([M +Na+]), calc. for [C34H32ClNO3+Na+] 560.1963; HPLC analysis: [α]D29=+40.9 (c 2.88, CHCl3); Chiralcel OD-H (Hex/IPA=95/5, 0.5 mL/min, 230 nm, 23° C.), 10.1 (major), 16.9 min, 92% ee.
Colorless oil; 96% yield. 1H NMR (500 MHz, CDCl3) δ 7.99-7.93 (m, 2H), 7.68-7.66 (m, 2H), 7.57-7.53 (m, 1H), 7.47-7.40 (m, 3H), 7.40-7.31 (m, 5H), 7.31-7.27 (m, 2H), 7.06-7.01 (m, 2H), 6.75 (d, J=6.9 Hz, 2H), 4.19-4.10 (m, 2H), 3.79-3.69 (m, 1H), 3.65-3.56 (m, 1H), 1.34 (s, 9H); 13C NMR (126 MHz, CDCl3) δ 198.4, 171.4, 169. 8, 140.6, 139.2, 137.1, 136.2, 133.0, 131.2, 130.5, 130.3, 128.8, 128.5, 128.4, 128.3, 128.2, 128.1, 127.5, 120.4, 81.6, 70.6, 44.2, 39.7, 27.9; LRMS (ESI) m/z 604.0 (M +Na+), HRMS (ESI) m/z 604.1262 ([M +Na+]), calc. for [C34H32BrNO3+Na+] 604.1458; [α]D29=+36.7 (c 2.73, CHCl3); HPLC analysis: Chiralcel OD-H (Hex/IPA=95/5, 0.5 mL/min, 230 nm, 23° C.), 10.2 (major), 16.7 min, 92% ee.
Colorless oil; 91% yield. 1H NMR (500 MHz, CDCl3) δ 8.05 (m, 2H), 7.97-7.95 (m, 2H), 7.68-7.66 (m, 2H), 7.58-7.55 (m, 1H), 7.48-7.31 (m, 10H), 6.75 (d, J =7.1 Hz, 2H), 4.31-4.27 (m, 1H), 4.20 (d, J=4.8 Hz, 1H), 3.87 (dd, J=17.6, 10.5 Hz, 1H), 3.69 (dd, J=17.6, 3.6 Hz, 1H), 1.36 (s, 9H); 13C NMR (75 MHz, CDCl3) δ 197.9, 171.9, 169.4, 149.6, 146.6, 138.9, 136.7, 135.9, 133.2, 130.7, 129.4, 128.8, 128.6, 128.4, 128.2, 128.1, 127.3, 123.3, 81.9, 69.9, 44.4, 39.5, 27.9; LRMS (ESI) m/z 571.1 (M +Na+), HRMS (ESI) m/z 571.2187 ([M+Na+]), calc. for [C34H32N2O5+Na+] 571.2203; [α]D29=+26.1 (c 3.00, CHCl3); HPLC analysis: Chiralcel OD-H (Hex/IPA=92/8, 0.8 mL/min, 230 nm, 23° C.), 8.9 (major), 13.9 min, 94% ee.
Colorless oil; 93% yield. 1H NMR (500 MHz, CDCl3) δ 8.05-7.98 (m, 2H), 7.69-7.61 (m, 2H), 7.55 (t, J=7.4 Hz, 1H), 7.50-7.42 (m, 2H), 7.42-7.37 (m, 1H), 7.34 (q, J=7.1 Hz, 3H), 7.29-7.23 (m, 3H), 7.18 (dd, J=7.3, 2.0 Hz, 1H), 7.09-7.03 (m, 2H), 6.57 (d, J=6.7 Hz, 2H), 4.73 (dt, J=10.4, 4.0 Hz, 1H), 4.31 (d, J=4.2 Hz, 1H), 3.99 (dd, J=17.3, 10.5 Hz, 1H), 3.70 (dd, J=17.3, 3.9 Hz, 1H), 1.39 (s, 9H); 13C NMR (126 MHz, CDCl3) δ 198.4, 171.6, 170.0, 139.3, 138.6, 137.1, 136.2, 134.5, 132.9, 130.3, 129.6, 129.2, 128.8, 128.5, 128.4, 128.2, 128.2, 128.0, 127.6, 127.3, 126.3, 81.4, 67.9, 40.7, 38.7, 27.9; LRMS (ESI) m/z 560.1 (M+Na+), HRMS (ESD m/z 560.1962 ([M+Na+]), calc. for [C34H32ClNO3+Na+] 560.1963; [α]D29=+72.4 (c 2.55, CHCl3); HPLC analysis: Chiralcel OD-H (Hex/IPA=95/5, 0.5 mL/min, 230 nm, 23° C.), 11.0 (major), 13.7 min, 94% ee.
Colorless oil; 89% yield. 1H NMR (500 MHz, CDCl3) δ 7.97-7.95 (m, 2H), 7.70-7.68 (m, 2H), 7.54-7.51 (m, 1H), 7.45-7.31(m, 8H), 7.07-7.05 (m, 2H), 6.78 (d, J=6.9 Hz, 2H), 6.72-6.70 (m, 2H), 4.16-4.14 (m, 2H), 3.72 (s, 3H), 3.67-3.63 (m, 1H), 3.60-3.56 (m, 1H), 1.32 (s, 9H); 13C NMR (126 MHz, CDCl3) δ 198.9, 171.1, 170.1, 158.3, 139.43, 137.3, 136.4, 133.4, 132.8, 130.3, 129.5, 128.9, 128.5, 128.4, 128.2, 128.2, 128.0, 127.6, 113.5, 81.2, 71.1, 55.2, 44.2, 40.4, 27.9; LRMS (ESD m/z 556.1 (M+Na+), HRMS (ESD m/z 556.2444 ([M+Na+]), calc. for [C35H35NO4+Na+] 556.2458; [α]D29=+52.7 (c 2.34, CHCl3); HPLC analysis: Chiralcel OD-H (Hex/IPA=90/10, 1.0 mL/min, 254 nm, 23° C.), 5.4 (major), 9.2 min, 85% ee.
Colorless oil; 90% yield. 1H NMR (500 MHz, CDCl3) δ 7.92-7.90 (m, 2H), 7.68-7.65 (m, 2H), 7.42-7.40 (m, 3H), 7.37-7.29 (m, 5H), 7.18-7.12 (m, 5H), 6.70 (d, J=7.0 Hz, 2H), 4.19-4.15 (m, 2H), 3.71-3.65 (m, 1H), 3.61 (dd, J=16.6, 3.6 Hz, 1H), 1.32 (s, 9H); 13C NMR (126 MHz, CDCl3) δ 197.6, 171.3, 167.0, 141.3, 139.4, 139.2, 136.3, 135.5, 130.4, 129.7, 128.8, 128.8, 128.5, 128.4, 128.2, 128.2, 128.1, 127.5, 126.7, 81.4, 70.8, 44.9, 40.1, 27.9; LRMS (ESI) m/z 560.1 (M +Na+), HRMS (ESI) m/z 560.1951 ([M+Na+]), calc. for [C34H32ClNO3+Na+] 560.1963; [α]D29=+44.2 (c 2.12, CHCl3); HPLC analysis: Chiralcel OD-H (Hex/IPA=95/5, 0.5 mL/min, 254 nm, 23° C.), 11.6 (major), 18.1 min, 92% ee.
Colorless oil: 91% yield. 1H NMR (500 MHz, CDCl3) δ 8.28-8.27 (m, 2H), 8.10-8.08 (m, 2H), 7.66-7.65 (m 2H), 7.42-7.41 (m, 1H), 7.37-7.34 (m, 3H), 7.30 (t, J=7.5 Hz, 2H), 7.18-7.11 (m, 5H), 6.68 (d, J=7.1 Hz, 2H), 4.18-4.14 (m, 2H), 3.78-3.68 (m, 2H), 1.32 (s, 9H); 13C NMR (126 MHz, CDCl3) δ 197.5, 171.5, 169.9, 150.2, 141.7, 141.0, 139.3, 136.2, 130.5, 129.2, 128.8, 128.5, 128.4, 128.3, 128.2, 128.1, 127.4, 126.8, 123.7, 81.5, 70.6, 44.8, 40.7, 27.9; LRMS (ESI) m/z 571.1 (M+Na+), HRMS (ESI) m/z 571.2188 ([M+Na+]), calc. for [C34H32N2O5+Na+] 571.2203; [α]D29=+36.5 (c 2.70, CHCl3); HPLC analysis: Chiralcel OD-H (Hex/IPA=92/8, 0.8 mL/min, 210 nm, 23° C.), 12.9 (major), 15.1 min, 91% ee.
Colorless oil; 83% yield. 1H NMR (500 MHz, CDCl3) δ 7.96 (d, J=8.8 Hz, 2H), 7.69-7.67 (m, 2H), 7.41-7.30 (m, 6H), 7.15-7.11 (m, 5H), 6.92 (t, J=5.8 Hz, 2H), 6.72 (d, J=6.8 Hz, 2H), 4.21-4.17 (m, 2H), 3.86 (s, 3H), 3.72-3.66 (m, 1H), 3.56-3.52 (m, 1H), 1.32 (s, 9H); 13C NMR (126 MHz, CDCl3) δ 197.2, 171.1, 170.1, 163.3, 141.4, 139.4, 136.3, 130.5, 130.4, 130.3, 128.9, 128.6, 128.4, 128.2, 128.1, 128.0, 127.5, 126.5, 113.6, 81.3, 71.0, 55.4, 45.0, 39.7, 27.9; LRMS (ESI) m/z 556.1 (M+Na+), HRMS (ESI) m/z 556.2446 ([M+Na+]), calc. for [C35H35NO4+Na+] 556.2458; [α]D29=+18.0 (c 2.73, CHCl3); HPLC analysis: Chiralcel OD-H (Hex/IPA=90/10, 1.0 mL/min, 254 nm, 23° C.), 6.4 (major), 11.8 min, 87% ee.
Colorless oil; 80% yield. 1H NMR (500 MHz, CDCl3) δ 8.55 (s, 1H), 8.01-7.98 (m, 2H), 7.86 (d, J=8.4 Hz, 2H), 7.71-7.70 (m, 2H), 7.60-7.54 (m, 2H), 7.42-7.30 (m, 6H), 7.19-7.13 (m, 5H), 6.73 (d, J=6.8 Hz, 2H), 4.29-4.24 (m, 1H), 4.22 (d, J=5.1 Hz, 1H), 3.89 (dd, J=16.7, 10.0 Hz, 1H), 3.76 (dd, J=16.7, 3.9 Hz, 1H), 1.33 (s, 9H); 13C NMR (126 MHz, CDCl3) 8 198.7, 171.3, 170.1, 141.4, 139.5, 136.4, 135.5, 134.6, 132.6, 130.3, 129.8, 129.6, 128.9, 128.6, 128.4, 128.3, 128.2, 128.2, 128.1, 127.7, 127.5, 126.6, 126.6, 124.1, 81.3, 71.0, 45.0, 40.1, 27.9; LRMS (ESI) m/z 576.1 (M +Na+), HRMS (ESI) m/z 576.2485 ([M +Na+]), calc. for [C38H35NO3+Na+] 576.2509; [α]D29=+8.0 (c 2.00, CHCl3); HPLC analysis: Chiralcel OD-H (Hex/IPA=90/10, 1.0 mL/min, 210 nm, 23° C.), 5.6 (major), 7.2 min, 91% ee.
Colorless oil; 95% yield. 1H NMR (500 MHz, CDCl3) δ 7.68-7.66 (m, 2H), 7.53-7.53 (m, 1H), 7.42-7.29 (m, 6H), 7.17-7.10 (m, 6H), 6.74 (d, J=6.9 Hz, 2H), 6.47 (dd, J=3.5, 1.6 Hz, 1H), 4.21-4.15 (m, 1H), 4.16 (d, J=5.4 Hz, 1H), 3.57 (dd, J=16.3, 9.8 Hz, 1H), 3.42 (dd, J=16.3, 4.2 Hz, 1H), 1.31 (s, 9H); 13C NMR (126 MHz, CDCl3) δ 187.8, 171.1, 169.9, 153.0, 146.0, 141.1, 139.4, 136.3, 130.3, 128.9, 128.6, 128.4, 128.2, 128.1, 128.0, 127.6, 126.6, 116.9, 112.1, 81.3, 70.9, 44.7, 40.1, 36.6, 27.8, 24.7; LRMS (ESI) m/z 516.1 (M+Na+), HRMS (ESI) m/z 516.2135 ([M+Na+]), calc. for [C32H31NO4+Na+] 516.2145; [α]D29=+52.1 (c 2.13, CHCl3); HPLC analysis: Chiralcel OD-H (Hex/IPA=90/10, 1.0 mL/min, 254 nm, 23° C.), 6.1 (major), 10.7 min, 90% ee.
Colorless oil; 92% yield. 1H NMR (500 MHz, CDCl3) δ 7.82 (dd, J=3.8, 1.0 Hz, 1H), 7.69-7.66 (m, 2H), 7.57 (dd, J=4.9, 1.0 Hz, 1H), 7.26-7.42 (m, 6H), 7.18-7.10 (m, 6H), 6.72 (d, J=7.0 Hz, 2H), 4.21-4.16 (m, 2H), 3.66 (dd, J=16.3, 9.6 Hz, 1H), 3.53 (dd, J=16.3, 3.7 Hz, 1H), 1.32 (s, 9H); 13C NMR (126 MHz, CDCl3) δ 191.5, 171.2, 170.0, 144.7, 141.1, 139.4, 136.3, 133.3, 131.9, 130.3, 128.9, 128.6, 128.4, 128.2, 128.2, 128.0, 128.0, 127.5, 126.6, 81.4, 70.9, 45.1, 40.8, 27.9; LRMS (ESI) m/z 532.1 (M+Na+), HRMS (ESI) m/z 532.1902 ([M+Na+]), calc. for [C32H31NO3S+Na] 532.1917; [α]D29=+67.7 (c 2.36, CHCl3); HPLC analysis: Chiralcel OD-H (Hex/IPA=95/5, 0.5 mL/min, 230 nm, 23° C.), 13.3 (major), 35.5 min, 90% ee.
All of the features disclosed in this specification may be combined in any combination. Each feature disclosed in this specification may be replaced by an alternative feature serving the same, equivalent, or similar purpose. Thus, unless expressly stated otherwise, each feature disclosed is only an example of a generic series of equivalent or similar features.
From the above description, one skilled in the art can easily ascertain the essential characteristics of the present invention, and without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various usages and conditions. Thus, other embodiments are also within the scope of the following claims.
| Filing Document | Filing Date | Country | Kind | 371c Date |
|---|---|---|---|---|
| PCT/SG2011/000378 | 10/27/2011 | WO | 00 | 4/26/2013 |
| Number | Date | Country | |
|---|---|---|---|
| 61407499 | Oct 2010 | US |
